Latest News

Leadiant Biosciences announces FDA approval of Revcovi for treating pediatric, adult ADA-SCID patients

Leadiant Biosciences, Inc. today announced that the Food and Drug Administration has granted approval to Revcovi (elapegademase-lvlr) injection in the U.S. Revcovi is a new enzyme replacement therapy for the treatment of adenosine deaminase severe combined immune deficiency in pediatric and adult patients.

Source link

Related posts

Sperm quality unaffected by one course of chemotherapy for early testicular cancer


Normalised behaviour of a non-plastic silt–pumice sand mixture


Medical News Today: Over 70% of US adults unaware of HPV-related cancer risks


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy